Micellar curcumin improves the antibacterial activity of the alkylphosphocholines erufosine and miltefosine against pathogenic Staphyloccocus aureus strains

References

• Dorlo TP, Balasegaram M, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67:2576–2597.
   PubMed Web of Science ®Google Scholar
• Jaffrés P-A, Gajate C, Bouchet AM, et al. Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy. Pharmacol Ther. 2016;165:114–131.
   PubMed Web of Science ®Google Scholar
• Rios-Marco P, Marco C, Galvez X, et al. Alkylphospholipids: an update on molecular mechanisms and clinical relevance. Biochim Biophys Acta Biomembr. 2017;1859:1657–1667.
   PubMed Web of Science ®Google Scholar
• Berger MR, Yanapirut P, Reinhardt M, et al. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas. Prog Exp Tumor Res. 1992;34:98–115.
   PubMed Web of Science ®Google Scholar
• Eibl H, Hilgard C, Unger C, editors. Alkylphosphocholines: New drugs in cancer therapy. Basel (Switzerland): Karger; 1992. (Prog Tumor Res, Vol. 34).
   Google Scholar
• Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet. 2005;366:1561–1577.
   PubMed Web of Science ®Google Scholar
• Varela MR, Villa-Pulgarin JA, Yepes E, et al. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl Trop Dis. 2012;6:e1612. DOI: 10.1371/journal.pntd.0001612
   PubMed Web of Science ®Google Scholar
• Le Fichoux Y, Rousseau D, Ferrua B, et al. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother. 1998;42:654–658.
   PubMed Web of Science ®Google Scholar
• Kuhlencord A, Maniera T, Eibl H, et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother. 1992;36:1630–1634.
   PubMed Web of Science ®Google Scholar
• Coelho AC, Trinconi CT, Costa CH, et al. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. PLoS Negl Trop Dis. 2014 ;8:e2999. DOI: 10.1371/journal.pntd.0002999
   PubMed Web of Science ®Google Scholar
• Konstantinov SM, Kaminsky R, Brun R, et al. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Acta Trop. 1997;64:145–154.
   PubMed Web of Science ®Google Scholar
• Seifert K, Duchene M, Wernsdorfer WH, et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother. 2001;45:1505–1510.
   PubMed Web of Science ®Google Scholar
• Eissa MM, El-Azzouni MZ, Amer EI, et al. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol. 2011;41:235–242.
   PubMed Web of Science ®Google Scholar
• Choubey V, Maity P, Guha M, et al. Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism. Antimicrob Agents Chemother. 2007;51:696–706.
   PubMed Web of Science ®Google Scholar
• Llull D, Rivas L, Garcia E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob Agents Chemother. 2007;51:1844–1848.
   PubMed Web of Science ®Google Scholar
• Obando D, Widmer F, Wright LC, et al. Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorg Med Chem. 2007;15:5158–5165.
   PubMed Web of Science ®Google Scholar
• Widmer F, Wright LC, Obando D, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother. 2006;50:414–421.
   PubMed Web of Science ®Google Scholar
• Tong Z, Widmer F, Sorrell TC, et al. In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agents Chemother. 2007;51:2219–2222.
   PubMed Web of Science ®Google Scholar
• Berger MR, Betsch B, Gebelein M, et al. Hexadecylphosphocholine differs from conventional cytostatic agents. J Cancer Res Clin Oncol. 1993;119:541–548.
   PubMed Web of Science ®Google Scholar
• Berger MR, Muschiol C, Schmähl D, et al. New cytostatics with experimentally different toxic profiles. Cancer Treat Rev. 1987;14:307–317.
   PubMed Web of Science ®Google Scholar
• Croft SL, Engel J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg. 2006 ;100 Suppl 1:S4–S8. DOI: S0035–9203(06)00197–0.
   PubMed Web of Science ®Google Scholar
• Tsushima S, Yoshioka Y, Tanida S, et al. Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem Pharm Bull. 1982;30:3260–3270.
   PubMed Web of Science ®Google Scholar
• Achterberg V, Gercken G. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol Biochem Parasitol. 1987;23:117–122.
   PubMed Web of Science ®Google Scholar
• Croft SL, Neal RA, Pendergast W, et al. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol. 1987;36:2633–2636.
   PubMed Web of Science ®Google Scholar
• German Drug Registration Authorities [Internet]. Impavido 10/50 mg Kapseln - Fachinformation. 2008 – [Cited 2018 Feb 1]. Available from: http://www.pharmnet-bund.de/dynamic/de/index.html
   Google Scholar
• Unger C, Sindermann H, Peukert M, et al. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res. 1992;34:153–159.
   PubMed Web of Science ®Google Scholar
• Who Model List of Essential Medicines - 17th List. Geneva (Switzerland): World Health Organization; c2011 [Cited 2018 Feb 1]. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/index.html
   Google Scholar
• Huelves L, Del Prado G, Gracia M, et al. In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. J Chemother. 2008;20:441–444.
   PubMed Web of Science ®Google Scholar
• Konigs SK, Pallasch CP, Lindner LH, et al. Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk Res. 2010;34:1064–1069.
   PubMed Web of Science ®Google Scholar
• Kapoor V, Zaharieva MM, Das SN, et al. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett. 2012;319:39–48.
   PubMed Web of Science ®Google Scholar
• Fiegl M, Lindner LH, Juergens M, et al. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol. 2008;62:321–329.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Papa V, Tazzari PL, et al. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia. 2010;24:687–698.
   PubMed Web of Science ®Google Scholar
• Yosifov DY, Todorov PT, Zaharieva MM, et al. Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother Pharmacol. 2011;67:13–25.
   PubMed Web of Science ®Google Scholar
• Ansari SS, Sharma AK, Zepp M, et al. Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells. Oncotarget. 2017;9:5797–5810.
   PubMedGoogle Scholar
• Kapoor V, Zaharieva MM, Berger MR. Erufosine induces autophagy and apoptosis in oral squamous cell carcinoma: role of the Akt-mTOR signaling pathway. In: Hayat MA, editor. Autophagy: Cancer, other pathologies, inflammation, immunity, infection, and aging. Mitophagy. Vol.3, 1st ed. Amsterdam: Academic Press - Elsevier; 2014. p. 229–245.
   Google Scholar
• Yosifov DY, Kaloyanov KA, Guenova ML, et al. Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk Res. 2014;38:49–56.
   PubMed Web of Science ®Google Scholar
• Zaharieva MM, Trochopoulos A, Dimitrov L, et al. New insights in routine procedure for mathematical evaluation of in vitro cytotoxicity data from cancer cell lines. Int J Bioautomation. 2018;22:87–106.
   Google Scholar
• Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sézary syndrome. JAMA. 1992;267:1354–1358.
   PubMed Web of Science ®Google Scholar
• de Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol. 2009;70:183–194.
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87:504–508.
   PubMed Web of Science ®Google Scholar
• Willerslev-Olsen A, Krejsgaard T, Lindahl LM, et al. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel). 2013;5:1402–1421.
   PubMed Web of Science ®Google Scholar
• Zhu C, Wang Y, Cai C, et al. Bacterial infection and associated cancers. Adv Exp Med Biol. 2017;1018:181–191.
   PubMed Web of Science ®Google Scholar
• Oliveira AS, Sousa E, Vasconcelos MH, et al. Curcumin: a natural lead for potential new drug candidates. Curr Med Chem. 2015;22:4196–4232.
   PubMed Web of Science ®Google Scholar
• Perrone D, Ardito F, Giannatempo G, et al. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med. 2015;10:1615–1623.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–818.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453–470.
   PubMed Web of Science ®Google Scholar
• Bhawana BRK, BHS, et al. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem. 2011;59:2056–2061.
   PubMed Web of Science ®Google Scholar
• Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S. Nanotechnology-applied curcumin for different diseases therapy. Biomed Res Int. 2014;2014:1–23. DOI: 10.1155/2014/394264
   Web of Science ®Google Scholar
• Krausz AE, Adler BL, Cabral V, et al. Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine. 2015;11:195–206.
   PubMed Web of Science ®Google Scholar
• Gopal J, Muthu M, Chun SC. Water soluble nanocurcumin extracted from turmeric challenging the microflora from human oral cavity. Food Chem. 2016;211:903–909.
   PubMed Web of Science ®Google Scholar
• Jahanizadeh S, Yazdian F, Marjani A, et al. Curcumin-loaded chitosan/carboxymethyl starch/montmorillonite bio-nanocomposite for reduction of dental bacterial biofilm formation. Int J Biol Macromol. 2017;105:757–763.
   PubMed Web of Science ®Google Scholar
• Tiwari B, Pahuja R, Kumar P, et al. Nanotized curcumin and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antimicrob Agents Chemother. 2017;61:e01169–e01116. DOI: 10.1128/aac.01169–16
   PubMed Web of Science ®Google Scholar
• Goncalves da Silva A, Baines SL, Carter GP, et al. A phylogenomic framework for assessing the global emergence and evolution of clonal complex 398 methicillin-resistant Staphylococcus aureus. Microb Genom. 2017;3:e000105. DOI: 10.1099/mgen.0.000105
   PubMed Web of Science ®Google Scholar
• Monaco M, Pimentel de Araujo F, Cruciani M, et al. Worldwide Epidemiology and Antibiotic Resistance of Staphylococcus aureus. In: Bagnoli F, Rappuoli R, Grandi G, editors. Staphylococcus aureus: microbiology, pathology, immunology, therapy and prophylaxis. Cham: Springer; 2016. p. 21–56.
   Google Scholar
• Metcalf D, Bowler P, Parsons D. Wound biofilm and therapeutic strategies. In: Dhanasekaran D, editor. Microbial biofilms. London (UK): IntechOpen; 2016. DOI: 10.5772/63238
   Google Scholar
• Sonderholm M, Bjarnsholt T, Alhede M, et al. The consequences of being in an infectious biofilm: Microenvironmental conditions governing antibiotic tolerance. IJMS. 2017;18:2688. DOI: 10.3390/ijms.18122688
   Google Scholar
• Kabanov AV, Batrakova EV, Melik-Nubarov NS, et al. A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J Controlled Release. 1992;22:141–157.
   Web of Science ®Google Scholar
• ISO20776/1 –2006. Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. European Committee for Standardization (CEN), Technical Committee CEN/TC 140, Technical Committee ISO/TC 212. 2006. p. 19.
   Google Scholar
• EUCAST: managing infections promoting science [Internet]. Basel (Switzerland): The European Committee on Antimicrobial Susceptibility Testing - EUCAST; c2018. Clinical breakpoints. Breakpoint tables for bacteria; 2013 Apr 07 [cited 2018 Jun 23]. Available from: http://www.eucast.org/clinical_breakpoints/
   Google Scholar
• Wang H, Cheng H, Wang F, et al. An improved 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction assay for evaluating the viability of Escherichia coli cells. J Microbiol Methods. 2010;82:330–333.
   PubMed Web of Science ®Google Scholar
• Lambert RJW, Lambert R. A model for the efficacy of combined inhibitors. J Appl Microbiol. 2003;95:734–743.
   PubMed Web of Science ®Google Scholar
• Stepanovic S, Vukovic D, Hola V, et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007;115:891–899.
   PubMed Web of Science ®Google Scholar
• Jenkins SG, Schuetz AN. Current concepts in laboratory testing to guide antimicrobial therapy. Mayo Clin Proc. 2012;87:290–308.
   PubMed Web of Science ®Google Scholar
• Lukac M, Garajova M, Mrva M, et al. Relationship between aggregation properties and antimicrobial activities of alkylphosphocholines with branched alkyl chains. Int J Pharm. 2012;423:247–256.
   PubMedGoogle Scholar
• Teow SY, Liew K, Ali SA, et al. Antibacterial action of curcumin against Staphylococcus aureus: a brief review. J Trop Med. 2016;2016:1–10. DOI: 10.1155/2016/2853045
   Google Scholar
• Moghadamtousi SZ, Kadir HA, Hassandarvish P, et al. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014;2014:1–12. DOI: 10.1155/2014/186864
   Google Scholar
• Mun SH, Kim SB, Kong R, et al. Curcumin reverse methicillin resistance in Staphylococcus aureus. Molecules. 2014;19:18283–18295.
   PubMed Web of Science ®Google Scholar
• Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2:114–122.
   PubMed Web of Science ®Google Scholar
• Makino T, Jimi S, Oyama T, et al. Infection mechanism of biofilm-forming Staphylococcus aureus on indwelling foreign materials in mice. Int Wound J. 2015;12:122–131.
   PubMed Web of Science ®Google Scholar
• Haraga I, Abe S, Jimi S, et al. Increased biofilm formation ability and accelerated transport of Staphylococcus aureus along a catheter during reciprocal movements. J Microbiol Methods. 2017;132:63–68.
   PubMed Web of Science ®Google Scholar
• Periasamy S, Joo HS, Duong AC, et al. How Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl Acad Sci USA. 2012;109:1281–1286.
   PubMed Web of Science ®Google Scholar
• Yocum RR, Rasmussen JR, Strominger JL. The mechanism of action of penicillin. Penicillin acylates the active site of Bacillus stearothermophilus D-alanine carboxypeptidase. J Biol Chem. 1980;255:3977–3986.
   PubMed Web of Science ®Google Scholar
• Mun SH, Joung DK, Kim YS, et al. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine. 2013;20:714–718.
   PubMed Web of Science ®Google Scholar
• Li L-M, Li J, Zhang X-Y. Antimicrobial and molecular interaction studies on derivatives of curcumin against Streptococcus pneumoniae which caused pneumonia. Electron J Biotechnol. 2016;19:8–14.
   Web of Science ®Google Scholar